Comparative in vitro and in vivo Bioequivalence Analysis of some Brands of film coated Atorvastatin (a BCS Class II Compound) tablets marketed in Nigeria

Simple item page
dc.contributor.authorOkorie, O.
dc.contributor.authorAzubuike, C.P.
dc.contributor.authorIlomuanya, M.
dc.contributor.authorUbani‑Ukoma, U.N.
dc.date.accessioned2020-02-24T11:17:37Z
dc.date.available2020-02-24T11:17:37Z
dc.date.issued2016
dc.descriptionStaff publicationsen_US
dc.description.abstractThe study is aimed at assessing the bioequivalence/quality of different brands of atorvastatin calcium 10mg tablets marketed in Nigeria. Physical parameters of the tablets, drug content, dissolution and pharmacokinetics data were assessed. The in vivo bioavailability study was carried out using a single dose randomized two period cross-over designs measuring the concentrations in plasma. Plasma samples before dosing and at various time intervals up to 48 hours after dosing were analysed using High-Performance Liquid Chromatography together with UV detector. Pharmacokinetics parameters (Cmax and AUC) were determined and subjected to statistical analysis. All brands complied with the official specification for uniformity of weight and disintegration time. Assay of atorvastatin tablets revealed that all samples contained atorvastatin calcium as their active ingredient between 91.4-102.1% (w/w) of labelled potency. The dissolution profiles showed inter brand variability. Four brands attained 70% dissolution within 45 minutes, however, at 60 minutes, all the brands released over 80% of the drug. In vivo bioavailability study showed that three out of the four brands were bioequivalent to the innovator brand and can be substituted for each other in their prescription. Chemical equivalence does not indicate bioequivalence and one brand substituted on assumption of chemical equivalence with another brand may not give the desired onset of action and therapeutic effectiveness. Moreover, dissolution test might not be enough for ascertaining bioequivalence of atorvastatin and in vivo tests may be required to ensure the quality of marketed brands of atorvastatin.en_US
dc.identifier.citationOkorie O. Azubuike C. P., Ilomuanya M. & Ubani-Ukoma U. (2016). Comparative in vitro and in vivo Bioequivalence Analysis of some Brands of film coated Atorvastatin (a BCS Class II Compound) tablets marketed in Nigeria. Journal of Reports in Pharmaceutical Sciences, 5(2), 112-121.en_US
dc.identifier.urihttps://ir.unilag.edu.ng/handle/123456789/7828
dc.language.isoenen_US
dc.relation.ispartofseriesJournal of Reports in Pharmaceutical Sciences;Vol.5(2)
dc.subjectAtorvastatinen_US
dc.subjectBioequivalenceen_US
dc.subjectGenericsen_US
dc.subjectInnovator Brandsen_US
dc.subjectPost Market Surveyen_US
dc.subjectResearch Subject Categories::PHARMACYen_US
dc.titleComparative in vitro and in vivo Bioequivalence Analysis of some Brands of film coated Atorvastatin (a BCS Class II Compound) tablets marketed in Nigeriaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Article 3.pdf
Size:
1.52 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Pharmaceutics and Pharmaceutical Technology- Scholarly Publications